NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: VERAXA Biotech’s H1 2026 Update on BiTAC Pipeline and Partnering Strategy
VERAXA Biotech provided a corporate update highlighting progress on its proprietary BiTAC platform, with four BiTAC-based T-cell engager programs targeting solid tumors and plans to advance lead candidate VXA-102 to IND/CTA readiness by early 2028. The company also noted strong industry interest in partnering and will prioritize BiTAC investment while monetizing non-BiTAC assets.
The update highlights progress in H1 2026 on its BiTAC platform, including four BiTAC-based T-cell engager programs targeting solid tumors, two bispecific ADC programs, and two non-BiTAC assets available for partnering.
BiTAC is VERAXA’s proprietary bispecific T-cell engager technology, designed to redirect T cells to kill tumor cells. It is a registered trademark of VERAXA Biotech GmbH.
VERAXA is prioritizing its lead BiTAC-TCE candidate VXA-102, with the goal of reaching IND/CTA readiness by early 2028.
The company plans to prioritize investment in its BiTAC portfolio while seeking to monetize selected non-BiTAC programs to help finance future development.
Company executives cited strong industry interest in T-cell engager and ADC technologies, reinforced by recent partnering discussions at the BIO International Convention and other scientific meetings.
VERAXA’s pipeline includes four BiTAC-based T-cell engager programs, two bispecific antibody-drug conjugate programs, and two non-BiTAC assets available for partnering.
VERAXA was founded on scientific breakthroughs at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research, lending credibility to its technology.
The full press release is available at https://ibn.fm/xTF5q. The latest news and updates for VRXA are available in the company’s newsroom at http://ibn.fm/VRXA.